Deutsche Bank AG Invests $1.44 Million in Bruker Corporation $BRKR

Deutsche Bank AG acquired a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,914 shares of the medical research company's stock, valued at approximately $1,439,000.

Other large investors have also modified their holdings of the company. Orbis Allan Gray Ltd grew its holdings in Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock worth $702,256,000 after acquiring an additional 761,258 shares during the period. State Street Corp grew its stake in shares of Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock worth $180,700,000 after purchasing an additional 91,706 shares during the period. AQR Capital Management LLC lifted its stake in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP lifted its stake in shares of Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after purchasing an additional 270,000 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock valued at $111,488,000 after buying an additional 2,289,269 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Performance

Shares of BRKR opened at $57.08 on Friday. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $65.30. The company's 50 day simple moving average is $58.77 and its 200 day simple moving average is $48.00. The company has a market capitalization of $8.70 billion, a price-to-earnings ratio of -81.54, a PEG ratio of 1.75 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same quarter in the prior year, the company posted $0.32 EPS. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker's payout ratio is currently -28.57%.

Analyst Ratings Changes

BRKR has been the subject of several research analyst reports. UBS Group set a $60.00 price objective on Bruker in a research note on Wednesday, June 24th. Leerink Partners raised their price target on Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research report on Tuesday, July 7th. Weiss Ratings raised Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research note on Wednesday, June 3rd. Wall Street Zen raised shares of Bruker from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, TD Cowen restated a "hold" rating on shares of Bruker in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source